Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

54.00 +0.16 (+0.30%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 868,065
Open 53.54
Bid (Size) 52.80 (1)
Ask (Size) 54.60 (1)
Prev. Close 53.84
Today's Range 53.33 - 54.17
52wk Range 42.01 - 70.50
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth investing. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers a rare mix of strong growth, profitability, and financial health at an attractive valuation, making it a standout in the biotech sector. 
Via Chartmill

Performance

YTD
+12.5%
+12.5%
1 Month
+1.3%
+1.3%
3 Month
-12.8%
-12.8%
6 Month
+12.5%
+12.5%
1 Year
+3.8%
+3.8%

More News

Read More
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
Via Chartmill
What's Driving the Market Sentiment Around Halozyme Therapeutics?
Via Benzinga
Price Over Earnings Overview: Halozyme Therapeutics
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
Via Chartmill
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
Via Chartmill
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Crude Oil Gains 3%; US Inflation Eases In April
Via Benzinga
Topics Economy
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
Via Investor's Business Daily
Topics Economy Government
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – An Undervalued Biotech Stock Worth Watching
Via Chartmill
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Insights into Halozyme Therapeutics's Upcoming Earnings
Via Benzinga
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable.
Via Chartmill
Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief
Via Stocktwits
Topics Intellectual Property Lawsuit

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 54.00
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 07/03/25 01:00 PM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 7.69B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.